199 related articles for article (PubMed ID: 2827081)
1. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
2. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
Iwasaka T; Ohkuma Y; Yoshimura T; Sugimori H
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378
[TBL] [Abstract][Full Text] [Related]
5. CA125 antigen levels in obstetric and gynecologic patients.
Niloff JM; Knapp RC; Schaetzl E; Reynolds C; Bast RC
Obstet Gynecol; 1984 Nov; 64(5):703-7. PubMed ID: 6208522
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
Oishi T; Maruo T; Iwasaki M; Mochizuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors].
Suzuki M; Sekiguchi I; Tamada T; Sakurabayashi I; Kawai T
Rinsho Byori; 1985 Feb; 33(2):173-7. PubMed ID: 3858562
[No Abstract] [Full Text] [Related]
8. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
[TBL] [Abstract][Full Text] [Related]
9. Role of Ca 125 as tumor marker in ovarian carcinoma.
Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
Liu LY
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
[TBL] [Abstract][Full Text] [Related]
12. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
Kataoka A; Yakushiji M
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
[TBL] [Abstract][Full Text] [Related]
13. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
[TBL] [Abstract][Full Text] [Related]
15. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
17. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of the tumor marker CA125 in ovarian tumor (a cooperative study among 8 institutions)].
Kato T; Nishimura H; Hamai J; Yamabe T; Nakajima H; Nakano T; Noda K; Teshima K; Suzuki H; Ueda G
Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2338-45. PubMed ID: 3007640
[No Abstract] [Full Text] [Related]
19. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
[TBL] [Abstract][Full Text] [Related]
20. The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary.
van der Burg ME; Lammes FB; Verweij J
Surg Gynecol Obstet; 1993 Apr; 176(4):310-4. PubMed ID: 8460404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]